3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
135
Small Cell Lung Carcinoma
51
Lung Neoplasms
45
Melanoma
15
Carcinoma, Renal Cell
14
Carcinoma, Transitional Cell
10
Stomach Neoplasms
9
Neoplasms
9
Head and Neck Neoplasms
9
Carcinoma, Hepatocellular
9
Mesothelioma, Malignant
8
Colorectal Neoplasms
8
Urinary Bladder Neoplasms
7
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Breast Neoplasms
6
Uterine Cervical Neoplasms
5
Neoplasm Metastasis
5
Kidney Neoplasms
5
Carcinoma, Merkel Cell
5
Thoracic Neoplasms
4
Carcinoma, Neuroendocrine
4
Small Cell Lung Cancer Extensive Stage
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Mesothelioma
3
Lung Diseases
3
Gastrointestinal Neoplasms
3
Esophageal Neoplasms
3
Brain Neoplasms
3
Interventions
pembrolizumab
4
Nivolumab
4
Ipilimumab
2
Interleukin-2
2
Drug Therapy
2
Biopsy
2
poly ICLC
1
pertuzumab
1
osimertinib
1
montanide ISA 51
1
liposomal doxorubicin
1
cobimetinib
1
cemiplimab
1
cc-486
1
brodalumab
1
atezolizumab
1
Trastuzumab
1
Tissue Banks
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Quality of Life
1
Psychiatric Rehabilitation
1
Poly I-C
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
atezolizumab
×
Thoracic
×
Clear all
NCT04273061
2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2
Recruiting
200 enrolled